AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Soliris (eculizumab) — US product sales by Year
Soliris (eculizumab) — US product sales ($M) ($M)
AstraZeneca Soliris (eculizumab) — US product sales: $1,092M in FY2025, down 28.3% from a year earlier.
Where the FY2025 figure comes from
“|| Soliris | 1,837 | (29) | (28) | 1,092 | (28) | 405 | (9) | (1) | 200 | (52) | (53) | 140 | (32) | (31)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Soliris (eculizumab) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,092 | -28.3% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 1,523 | -12.2% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,734 | -20.5% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 2,180 | +104.1% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1,068 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up soliris (eculizumab) — US product sales
Cite this data
StockData. (2026). AstraZeneca Soliris (eculizumab) — US product sales ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-soliris-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.